Scinai Immunotherapeutics (SCNI) Cash & Equivalents (2015 - 2026)

Scinai Immunotherapeutics has reported Cash & Equivalents for 12 years, with the latest figure at $3.0 billion in Q1 2026.

• Quarterly Cash & Equivalents rose 257776.41% year-over-year to $3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 257776.41% YoY) and the FY2025 annual result came in at $1.7 million, down 15.43% from the prior year.
• Cash & Equivalents rose to $3.0 billion in Q1 2026 per SCNI's latest filing, from $1.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $3.0 billion in Q1 2026 and troughed at $1.1 million in Q2 2025.
• A 5-year average of $192.4 million and a median of $6.7 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents plunged 77.39% in 2024, then soared 257776.41% in 2026.
• Over 5 years, Cash & Equivalents stood at $14.1 million in 2022, then sank by 65.4% to $4.9 million in 2023, then tumbled by 59.67% to $2.0 million in 2024, then retreated by 15.43% to $1.7 million in 2025, then surged by 178286.51% to $3.0 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.0 billion, $1.7 million, and $1.1 million for Q1 2026, Q4 2025, and Q2 2025 respectively.